Peptide Price Finder

Home · Research · Longevity & bioregulators

Bronchogen research

What published studies found for Bronchogen: 5 papers, 0 in humans, with sample sizes and key results.

C
Mostly animal studies
Why: No human studies; two rat COPD-model studies from the developer's group plus cell, DNA and plant experiments.

Bronchogen (Ala-Glu-Asp-Leu, AEDL) is a St. Petersburg 'peptide bioregulator' marketed for the lungs; the evidence is two small rat COPD-model studies plus cell, DNA and even plant experiments, nearly all from the developer's network. No human studies were found.

✓ 2 positive? 3 inconclusive

No human safety or efficacy data in the published literature.

US compounding: Not compoundable. Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Status for every peptide.

Browse and filter these papersBronchogen prices and vendors

Animal & lab studies

✓ PositiveanimalBull Exp Biol Med · 2015

Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.

AnimalsTetrapeptide Bronchogen therapy in a rat COPD model1 month of treatment

In rats with NO2-induced COPD-like lung damage, one month of Bronchogen reportedly reversed bronchial epithelial remodeling (goblet cell hyperplasia, metaplasia, emphysema), increased secretory IgA and reduced neutrophilic inflammation.

Studied
Rats with COPD modeled by 60-day intermittent NO2 exposure
Main outcome
Bronchial epithelium remodeling, secretory IgA, cytokines
Authors' conclusion
One month of Bronchogen eliminated signs of bronchial epithelium and lung remodeling, raised secretory IgA and normalized cell composition and proinflammatory cytokines, reflecting reduced neutrophilic inflammation.
Limitations
Rat model; sample size not stated in abstract.
PubMed 26468022DOI
✓ PositiveanimalRoss Fiziol Zh Im I M Sechenova · 2017

[ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY].

AnimalsBronchogen course with bronchoalveolar lavage analysis

Same rat COPD model: Bronchogen normalized lavage-fluid cell composition and pro-inflammatory cytokines and raised secretory IgA and surfactant protein B.

Studied
Rats with COPD modeled by 60-day intermittent nitrogen dioxide exposure
Main outcome
BALF cell composition, cytokines, secretory IgA, surfactant protein B
Authors' conclusion
Peptide treatment reduced neutrophilic inflammation, restored bronchial epithelium structure and increased secretory IgA and surfactant protein B.
Limitations
Rat model; sample size not stated in abstract.
PubMed 30199201
? Inconclusivein vitroBull Exp Biol Med · 2012

Peptides tissue-specifically stimulate cell differentiation during their aging.

Cells / labIn vitro expression study in young and late-passage (aging) cultures

In aging human bronchial epithelial cell cultures, Bronchogen stimulated expression of differentiation factors CXCL12 and Hoxa3.

Studied
Human embryonic pancreatic and bronchial cells and prostatic fibroblasts in culture
Main outcome
Expression of CXCL12, Hoxa3 and WEGC1 differentiation factors
Authors' conclusion
Vesugen stimulated differentiation factor expression in fibroblasts, with a stronger effect in aged cultures, which may be a mechanism of geroprotective effect.
Limitations
In vitro cell culture only.
PubMed 22808515DOI
? Inconclusivein vitroBiochemistry (Mosc) · 2015

Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells.

Cells / labIn vitro gene expression and promoter DNA-methylation analysis with KEDW and AEDL peptides

In aging bronchial cell cultures, AEDL altered expression of several lung genes (e.g. NKX2-1, SCGB1A1), possibly via promoter methylation changes; other genes were unaffected.

Studied
Ageing human pancreatic and bronchial epithelium cell cultures
Compared with
Untreated cultures of different age
Main outcome
Gene expression and promoter methylation of PDX1, PAX6, NGN3 and other genes
Authors' conclusion
Changes in promoter methylation might explain the age- and peptide-induced changes in expression of PDX1, PAX6 and NGN3 in pancreatic cells; other genes appear controlled by other mechanisms.
Limitations
Cell cultures only; mechanism, not efficacy.
PubMed 25761685DOI
? Inconclusivein vitroBull Exp Biol Med · 2011

Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability.

No new dataDifferential scanning microcalorimetry of DNA melting with bronchogen

Calorimetry study: Bronchogen raised the melting temperature of isolated DNA by 3.1 °C, acting as a DNA-stabilizing agent.

Key resultBronchogen increased the melting temperature of DNA by 3.1°C in a narrow range of molar ratios
Studied
DNA from calf thymus and mouse liver
Main outcome
DNA melting temperature and enthalpy
Authors' conclusion
Bronchogen acts as a DNA-stabilizing agent, not specific for AT or GC pairs, binding strongly and occasionally to both strands.
Limitations
Biophysical in vitro study.
PubMed 21240358DOI

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.